Powered by

Boston Scientific Launches DIRECTSENSE™ Technology; Tool provides electrophysiologists with first-ever local measurement and visualization of tissue response to radiofrequency ablation

Jun 01, 2020 - PR Newswire
Product Launch

PR Newswire

 Boston Scientific (NYSE: BSX) announced the U.S. launch of the DIRECTSENSE™ Technology, a tool for monitoring the effect of radiofrequency (RF) energy delivery during cardiac ablation procedures. Available on the RHYTHMIA HDx™ Mapping System, the DIRECTSENSE Technology, which received U.S. Food and Drug Administration approval in April, is the only tool to monitor changes in local impedance – electrical resistance – around the tip of the INTELLANAV™ MiFi Open-Irriga...